Hot Longevity Mandate: Europe-Based Pharma Company

19 Oct

The pharma is based in Europe. The company forms relationships with early-stage biotech companies, usually structured in the form of rights (worldwide, world excluding US & Japan, or regional rights), co-marketing, or R&D collaborations. The company may also consider participation in equity financing rounds. Recently, the company has entered an agreement to develop an incubator which is expected to open in 2023. The company is open to partnering with companies globally.

Currently, the company focuses on 5 disease areas: oncology, CNS, immune-inflammation (early-stage); cardiovascular disease, and metabolic disease (late-stage).

Within oncology, the company is interested in apoptosis (BCL2 family), novel oncogenes/oncogene stability regulators, epigenetic regulators (with biomarker validation), synthetic lethality associated with genetic defect, stroma/tumor microenvironment, T cell activation, immunosuppression, and innate immunity. In terms of modalities, the firm is primarily looking at small molecules (discovery to early clinical stage) and monoclonal antibodies/bispecifics (early clinical stage).

Within CNS, the firm is looking for small molecules, oligonucleotides, or PROTAC that address rare synucleinopathies, rare tauopathies, repeat expansion diseases, and amyotrophic lateral sclerosis by menas of clearance of toxic proteins and targeted degradation, as well as regulation of transcription and translation of targets. The company is not interested in epilepsy, multiple sclerosis, pain, psychiatry, or infectious diseases, and is currently not seeking antibodies, cell therapy, or vaccines.

Within immuno-inflammatory diseases, the company is most interested in lupus, systemic sclerosis, Sjögren syndrome, and other chronic inflammatory and fibrotic diseases that share similar pathophysiological mechanisms.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: